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Abstract
Pulmonary hypertension (PH) is a relatively frequent and severe complication of sickle cell disease (SCD).
PH associated with SCD is classified as Group 5 PH. The exact pathogenesis of PH in SCD in not known.
There are also very limited treatment options available at this time for such patients with Group 5 PH.
Patients with SCD are predisposed to a hypercoagulable state and thus can also suffer from chronic
thromboembolism. These patients can have associated chronic thromboembolic pulmonary hypertension
(CTEPH), thus being classified as Group 4 PH. We present such a case of a patient with SCD diagnosed
with severe PH who was found to have CTEPH and successfully underwent a thromboendarterectomy
with resolution of his symptoms such as reduction of his oxygen requirements and healing of chronic leg
ulcer. This case illustrates the importance of screening patients with SCD and elevated pulmonary artery
pressures for CTEPH as this would offer possible treatment options such as pulmonary
thromboendarterectomy and/or riociguat in this subset of patients.
KEY WORDS: Chronic thromboembolic pulmonary hypertension, leg ulcer, pulmonary hypertension,
pulmonary thromboendarterectomy, sickle cell disease
INTRODUCTION
Pulmonary hypertension (PH) is a relatively frequent and severe complication of sickle cell disease (SCD).
The exact pathogenesis of PH in SCD in not known, but a number of factors have been implicated. These
factors include endothelial injury due to recurrent sickling and associated vascular intimal hyperplasia,
acute and chronic inflammation, and altered bioavailability of nitric oxide (NO). The vascular intimal
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hyperplasia can occur with or without a superimposed thrombus and can lead to chronic
thromboembolism. Patients with PH secondary to SCD are classified as Group 5 PH as per the WHO
guidelines.[1] Patients who suffer from chronic thromboembolism secondary to SCD can also have
associated chronic thromboembolic pulmonary hypertension (CTEPH), thus being classified as Group 4
PH as per the WHO classification.[1] We present such a case of a patient with SCD diagnosed with severe
PH who was found to have CTEPH and successfully underwent a thromboendarterectomy with resolution
of symptoms.
CASE REPORT
A 37-year-old male with SCD (hemoglobin (Hb) SS-disease) (treated with blood transfusion every 3
months) was diagnosed with pulmonary embolism (PE) and was being treated with enoxaparin. Apart from
the SCD, the patient had a history of chronic venous stasis ulcer, which was being managed on an
outpatient basis [Figure 1]. Eighteen months after the diagnosis of PE, the patient presented to the
emergency department with worsening dyspnea on exertion. A ventilation/perfusion (VQ) scan was
performed at the time that showed a right middle lobe perfusion defect consistent with PE. Ultrasound of
both lower extremities revealed chronic deep vein thrombosis. The patient was also noted to have
nocturnal hypoxemia and hypoxemia with exertion and was thus started on home oxygen therapy.
For further evaluation, the patient had a computed tomography pulmonary angiogram (CTPA), which
demonstrated diffuse mosaic attenuation of lung parenchyma as seen in diseases such as chronic
thromboembolic (CTE) disease [Figure 2a and b]. A mildly dilated pulmonary artery was also noted [
Figure 2a]. A transthoracic echocardiogram showed right ventricular dilatation with estimated right
ventricular systolic pressure (RVSP) of 103 mmHg. His most recent previous echocardiogram was
performed 18 months ago and demonstrated a normal right ventricle with normal RVSP. A cardiac
catheterization was performed which showed elevated pulmonary artery pressures with normal left-sided
pressures [Table 1]. He was thus diagnosed with PH and started on sildenafil. Pulmonary function tests
showed a restrictive pattern with decreased diffusion capacity (DLCO) [Table 2]. The 6-min walk distance
(6MWD) was 416 M with supplemental oxygen at 5 L/min to keep the saturation above 90%. The patient
required 2 L/m of supplemental oxygen at baseline. He was thus referred to the cardiothoracic surgery
team for evaluation of CTEPH.
The pulmonary angiogram demonstrated filling defects in the right lower and middle lobes and left lower
lobe, consistent with CTE disease [Figure 3a and b]. Severely elevated pulmonary pressures were again
noted [Table 3]. Two months later, the patient underwent a successful pulmonary endarterectomy (PEA)
with removal of the thrombus [Figure 4]. He was also started on riociguat for residual PH and enrolled in
the cardiopulmonary rehabilitation program. His repeat 6MWD increased to 432 M without any
supplemental oxygen. Interestingly, on follow-up, it was also noted that the patient's chronic venous stasis
ulcer showed remarkable improvement with improvement in his oxygen saturation and improvement in his
functional status [Figure 5]. The patient continues to have a stable follow-up course.
DISCUSSION
PH is a common complication of SCD. The prevalence of PH in this patient group is around 10%–20%
and is a common cause of mortality.[2] Although there is evidence that patients with SCD have a
hypercoagulable state, CTEPH in these patients is relatively uncommon. According to a study by Anthi et
al., 23% of the SCD patients with PH had perfusion mismatch in the V/Q scan. About 11.5% of the
patients had evidence of CTE disease on CTPAs.[3]
There have been multiple pathophysiologic mechanisms which have been postulated which lead to
thromboembolism in SCD patients and subsequently can lead to CTEPH. In fact, every aspect of
Virchow's triad, i.e., increased coagulability, endothelial dysfunction, and impaired blood flow, is present
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in patients with SCD and results in a highly thrombogenic environment.[4]
The repeated cycles of sickling and unsickling in SCD patients lead to an abnormal phospholipid
asymmetry as well as adherence of the sickle erythrocytes to the vascular endothelium. The alteration of
the membrane structure of sickle erythrocytes results in exposure of the anionic phospholipid,
phosphatidylserine (PS). This phenomenon supports coagulation by PS acting as the cofactor for
proteolytic reactions.[5] This phenomenon is also supported by the fact that a correlation has been found
between PS-positive sickle cell erythrocytes and prothrombin fragments 1.2, D-dimers, and plasmin-
antiplasmin complex.[6] Antiphospholipid antibodies are known to be both procoagulant and
prothrombotic. Levels of these antibodies are markedly higher in patients with SCD.[7] These antibodies
work by tissue factor induction leading to activation of the coagulation system.[8] Multiple studies have
suggested that there is increased thrombin generation in SCD patients. Increased levels of prothrombin
fragments1.2, D-dimers, and thrombin-antithrombin complexes support this hypothesis.[9] The level of
factor V is also reduced in SCD patients suggesting ongoing thrombin generation.[10] Along with that,
high plasma levels of procoagulants such as von Willebrand factor and factor VIII are found in SCD
patients.[10,11,12] All these changes reflect the hypercoagulable state in SCD.
Circulating free Hb in the setting of hemolysis also causes NO depletion, which leads to chronic
vasoconstriction and platelet activation.[13] Moderate thrombocytosis is a common feature of patients with
SCD and sickle cell anemia. These changes can be attributed to the fact that splenic autoinfarction affects
the majority of children with Hb SS-disease by age 1 year and a large proportion of patients with SC
disease by middle childhood.[14] This could also lead to the development of secondary PH. Long-standing
thrombocytosis after splenectomy has been shown in one case to be associated with elevated
fibrinopeptide A, thromboxane B2, and β-thromboglobulin levels resulting in endothelial damage, local
platelet activation, and thrombin generation leading to CTEPH. A similar mechanism could lead to
CTEPH in SCD patients due to the functional asplenia.[15] Besides thrombocytosis, increased platelet
adhesion may contribute to the development of pulmonary vasculopathy. There is evidence to support
transmigration of intact megakaryocytes from the bone marrow to the circulation and the release of
platelets from these megakaryocytes in the pulmonary capillary bed. These large-sized platelet precursors
can contribute to distal in situ thrombosis leading to CTEPH in asplenic SCD patients.[16]
Transthoracic Doppler echocardiography on patients with SCD is a cost-effective and established
screening tool for PH. Elevated pulmonary artery systolic pressure on echocardiography should be
confirmed by right heart catheterization (RHC). Due to the high incidence of thromboembolism in patients
with SCD, patients with PH should be screened with a VQ scan and/or a CTPA. Patient with signs
suggestive of CTEPH should undergo an angiography to diagnose CTE. Pulmonary function tests should
be performed in all patients with SCD presenting with dyspnea. A restrictive pulmonary functional
abnormality in this setting may represent areas of prior infarction.[17]
The diagnosis of CTE and related CTEPH can alter management strategies and the classification of PH.
PH associated with SCD is classified as Group 5 PH. A recent guideline from the American Thoracic
Society proposes the screening for PH in patients with SCD every 3 years.[18] A different guideline by the
sickle cell expert panel did not endorse these recommendations, suggesting echocardiographic evaluation
followed by RHC in symptomatic patients only.[19] PH related to CTEPH is classified as Group 4 as per
the WHO classification system. Although PEA is recommended for patients with PH related to CTE
disease, chronic hemolysis and the associated proliferative vasculopathy in the distal vessels put patients
with SCD at increased risk of residual PH after PEA. CTEPH in SCD patients has been treated surgically
with success [Table 1]. Jerath et al.[20] demonstrated normalization of pulmonary artery pressures, after a
PEA in a patient with SCD and CTEPH. Deep hypothermic circulatory arrest (DHCA) during PEA
exposes the SCD patient to a hypothermic, hypoxic, acidotic, and a low-flow state. These patients are thus
at an increased risk of sickling during this procedure. While there is no consensus on the values of Hb S in
patients with SCD, Firth and Head have proposed that the level of Hb S should be reduced to <30% for a
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major surgical procedure and to <10% for a cardiopulmonary surgical procedure.[21] Five cases in
literature demonstrated a successful PEA under DHCA after exchange transfusion to reduced Hb S to
<10% [Table 4].[20,23,24] Attention should be paid to maintaining good flow states, a normal acid-base
balance status, and limit the duration of circulatory arrest periods. The use of specific PAH therapies for
the management of SCD-associated PH is a controversial matter. Two randomized control trials have
studied the role of bosentan but have been prematurely terminated.[25] Another trial addressing the role of
sildenafil was discontinued due to increased hospitalization for pain crisis.[26] To date, there have been no
studies to inform anticoagulation practices in patients with SCD.[27] Anticoagulation management of
symptomatic VTE and CTEPH, therefore, currently relies on established general guidelines for VTE
management.[28] Further studies are necessary to determine adequate treatment approach and to determine
which subgroup of patients might benefit from PAH-targeted therapies and anticoagulation.
Leg ulcerations have been a long-recognized complication of SCD. Minniti et al. in their review concluded
that the epidemiological relationship between leg ulcers and PH supported an overlap of pathobiological
mechanisms.[29] The possible overlapping mechanisms include mechanical obstruction by dense sickled
red cells, in situ thrombosis, anemia with decrease in oxygen carrying capacity, and decreased NO
bioavailability leading to impaired endothelial function.[30] One interesting case report has noted leg ulcer
healing during treatment of pulmonary arterial hypertension with an endothelin receptor antagonist.[31]
Management of PH is currently recommended as one of the systemic interventions for managing this
complication of SCD.[22] Our patient demonstrated healing of the ulcer after undergoing a successful
thromboendarterectomy for management of his CTEPH. We hypothesize that the possible mechanisms of
improvement of the leg ulcer include increased peripheral oxygen supply as evidenced by the decrease in
supplemental oxygen requirement. Another possible contributing factor is the reduction of right-sided
pressures after the endarterectomy leading to decreased venous stasis and decreased peripheral edema, thus
helping the healing of the ulcer.
CONCLUSION
We present a case of a 37-year-old male with SCD and associated Group 4 PH due to chronic
thromboembolism who underwent a successful PEA. This helped reduce his oxygen requirement,
increased his 6MWD, and also helped with healing of his chronic venous stasis ulcer, all likely
manifestations of his PH. Thus, the clinicians should screen and assess for CTEPH in patients with SCD
with elevated pulmonary artery pressures as this would offer possible treatment options such as pulmonary
thromboendarterectomy and/or riociguat in this subset of patients.
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Figure 1
Patient with leg ulcer with sickle cell disease and pulmonary hypertension
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Figure 2
(a and b) Computed tomography of the chest showing a diffuse mosaic attenuation of the lung parenchyma
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Table 1
Right heart catheterization
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Table 2
Pulmonary function tests (restrictive pattern with reduced diffusing capacity of the lungs for carbon
monoxide)
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Figure 3
(a) Pulmonary angiogram showing filling defects in the right middle lobe and right lower lobe. (b) Pulmonary angiogram
showing filling defects on the left side
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Table 3
Right heart catheterization/pulmonary angiography
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Figure 4
Clot removed after pulmonary thromboendarterectomy
9/25/2019 Successful pulmonary thromboendarterectomy in a patient with sickle cell disease and associated resolution of a leg ulcer
https://www-ncbi-nlm-nih-gov.medproxy.hofstra.edu/pmc/articles/PMC5760875/?report=printable 15/16
Figure 5
Healing lung ulcer status post pulmonary thromboendarterectomy
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Table 4
All reported patients with sickle cell disease who underwent pulmonary endarterectomy
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